{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:49:46Z","timestamp":1791344986109,"version":"4.3.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"DOI":"10.1186\/s13052-026-02297-4","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:35:17Z","timestamp":1783942517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Respiratory function in children and young adults affected by neurofibromatosis type 1 treated with selumetinib"],"prefix":"10.1186","volume":"52","author":[{"given":"Elettra","family":"Zuliani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7523-3154","authenticated-orcid":false,"given":"Francesco","family":"Baldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Ghirardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Magnolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Maschio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egidio","family":"Barbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"26","key":"2297_CR1","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi E, Baldwin A, Marcus LJ, et al. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med. 2016;375(26):2550\u201360.","journal-title":"N Engl J Med"},{"issue":"15","key":"2297_CR2","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med. 2020;382(15):1430\u201342.","journal-title":"N Engl J Med"},{"issue":"4","key":"2297_CR3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40272-020-00399-y","volume":"22","author":"F Baldo","year":"2020","unstructured":"Baldo F, Grasso AG, Cortellazzo Wiel L, et al. Selumetinib in the Treatment of Symptomatic Intractable Plexiform Neurofibromas in Neurofibromatosis Type 1: A Prospective Case Series with Emphasis on Side Effects. Paediatr Drugs. 2020;22(4):417\u201323.","journal-title":"Paediatr Drugs"},{"key":"2297_CR4","first-page":"24","volume":"28","author":"K Haslett","year":"2021","unstructured":"Haslett K, Koh P, Hudson A, et al. Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer. Clin Transl Radiat Oncol. 2021;28:24\u201331.","journal-title":"Clin Transl Radiat Oncol"},{"key":"2297_CR5","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1186\/s12885-015-1754-3","volume":"15","author":"V Giraud","year":"2015","unstructured":"Giraud V, Longvert C, Houlle-Crepin S, et al. Relapsing pneumonitis due to two distinct inhibitors of the MAPK\/ERK pathway: report of a case. BMC Cancer. 2015;15:732.","journal-title":"BMC Cancer"},{"key":"2297_CR6","doi-asserted-by":"crossref","unstructured":"Takashi Seto F, Hirai H, Saka, et al. Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer. Jpn J Clin Oncol. January 2018;48(1):31\u201342.","DOI":"10.1093\/jjco\/hyx144"},{"issue":"10324","key":"2297_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","volume":"399","author":"DM Gershenson","year":"2022","unstructured":"Gershenson DM, Miller A, Brady WE, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial. Lancet. 2022;399(10324):541\u201353.","journal-title":"Lancet"},{"key":"2297_CR8","doi-asserted-by":"publisher","unstructured":"Stanojevic S, Kaminsky DA, Miller MR, Thompson B, Aliverti A, Barjaktarevic I, Cooper BG, Culver B, Derom E, Hall GL, Hallstrand TS, Leuppi JD, MacIntyre N, McCormack M, Rosenfeld M, Swenson ER. ERS\/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022;60(1):2101499. https:\/\/doi.org\/10.1183\/13993003.01499-2021. PMID: 34949706.","DOI":"10.1183\/13993003.01499-2021"},{"issue":"11","key":"2297_CR9","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/neuonc\/noac109","volume":"24","author":"AM Gross","year":"2022","unstructured":"Gross AM, Glassberg B, Wolters PL, et al. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. Neuro Oncol. 2022;24(11):1978\u201388.","journal-title":"Neuro Oncol"},{"issue":"4","key":"2297_CR10","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/annonc\/mdw008","volume":"27","author":"CA Carter","year":"2016","unstructured":"Carter CA, Rajan A, Keen C, et al. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced non small-cell lung cancer. Ann Oncol. 2016;27(4):693\u20139.","journal-title":"Ann Oncol"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-026-02297-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-026-02297-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-026-02297-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:50:47Z","timestamp":1791341447000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13052-026-02297-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2297"],"URL":"https:\/\/doi.org\/10.1186\/s13052-026-02297-4","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"10 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All experimental protocols were approved by the IRCCS Burlo Garofolo ethics committee. Written consent was obtained from the parents of patients under 18 years old.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written consent was obtained from parents for participants under 18 years old. Written consent was obtained for the publication of potentially identifying images and clinical details.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Elettra Zuliani declares that she has no conflict of interest. Francesco Baldo declares that he has no conflict of interest. Sergio Ghirardo declares that he has no conflict of interest. Andrea Magnolato declares that he has no conflict of interest. Irene Bruno declares that she has no conflict of interest. Massimo Maschio declares that he has no conflict of interest. Egidio Barbi declares that he has no conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"150"}}